Cisse A, Lopez Sall P, Diop P A, Diop S N, Sylla Niang M, Ka Cisse M S, Gueye P M, Sarr A, Ndour Mbaye N M
Laboratoire de Biochimie Pharmaceutique, Faculté de Médecine, de Pharmacie et d'Odontostomatologie. Université Cheikh Anta DIOP, Dakar, Senegal.
Dakar Med. 2003;48(3):237-9.
Nephropathy is one of the complications occuring during diabetes and it is diagnosed via microalbuminuria. From 1992 to 1999, five hundred and eighty seven (587) diabetic patients were recruited and distributed into two groups, A (n = 270) and B (n = 317). Microalbuminuria was determined by immunonephelemetry for group A and immunoturbidimetry for group B. The results showed respectively 15.5% and 20.19% pathological cases in the two groups (NS). Considering the distribution of patients with microalbuminuria according to the type of diabetes, there were 16.12% type 1 and 15.07% type 2 in group A against 22.60% and 18.13% in group B; no statistically significant differences were observed either in the same group or from one group to another. These frequencies might reflect the situation in the nineties; they are lower than those encountered in other populations. Nevertheless monitoring is needed through a regular schedule to prevent nephropathy.
肾病是糖尿病期间发生的并发症之一,通过微量白蛋白尿进行诊断。1992年至1999年,招募了587名糖尿病患者并将其分为两组,A组(n = 270)和B组(n = 317)。A组通过免疫比浊法测定微量白蛋白尿,B组通过免疫散射比浊法测定。结果显示两组的病理病例分别为15.5%和20.19%(无显著性差异)。根据糖尿病类型考虑微量白蛋白尿患者的分布情况,A组1型糖尿病患者为16.12%,2型糖尿病患者为15.07%,而B组分别为22.60%和18.13%;在同一组内或两组之间均未观察到统计学上的显著差异。这些频率可能反映了九十年代的情况;它们低于其他人群中的频率。尽管如此,仍需要通过定期监测来预防肾病。